Antinuclear Antibody Test Market Size, Share, and Industry Analysis, By Product (Reagents & Assay Kits, Systems, and Standalone Consumables), By Test Method (Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay, Multiplex Immunoassays, and Others), By Indication (Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, Sjögren’s Syndrome, Scleroderma, and Others), By End-user (Hospitals, Standalone Laboratories, and Others), and Regional Forecast, 2026-2034

The antinuclear antibody test market size was valued at USD 41.89 million in 2025 and is expected to reach a market valuation of USD 47.67 million in 2026. Furthermore, the market is projected to reach a market valuation of USD 134.13 million by 2034, exhibiting a CAGR of 13.81% during the forecast period.

The global antinuclear antibody test market is experiencing significant growth due to increasing physician awareness and the expansion of diagnostic infrastructure in emerging economies. Moreover, technological advancements, particularly in automated immunofluorescence platforms and multiplex assays, are enhancing throughput and consistency of results, leading to wider adoption.

Furthermore, the major players are expanding their autoimmune diagnostics portfolios, further accelerating market penetration and supporting the market expansion.

Antinuclear Antibody Test Market Driver

Rising Prevalence of Autoimmune Diseases to Fuel Market Growth

In recent years, there has been a significant rise in prevalence and diagnosis rates of autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus. The incidence is expected to further increase due to the growing geriatric population. This is further increasing the demand for laboratory testing solutions, such as antinuclear antibody tests, which are anticipated to fuel market expansion over the forecast period.

• For instance, in June 2023, the World Health Organization (WHO) reported that out of the total patients with rheumatoid arthritis worldwide, 70.0% are women, and 55.0% are older than 55 years.

Download Free sample to learn more about this report.

According to data published by the Ampersand, in the U.K., approximately 1.5 men and 3.6 women develop RA annually per 10,000 people.

Antinuclear Antibody Test Market Restraint

Interpretation Variability and Standardization Challenges to Restrict Market Growth

Despite strong demand, the antinuclear test market faces challenges related to result interpretation and inter-laboratory variability, specifically with immunofluorescence-based assays. Manual reading of fluorescence patterns requires skilled personnel, and subjective interpretation can affect diagnostic consistency. Several smaller laboratories often lack trained immunologists, which is anticipated to limit the adoption in resource-constrained settings, hindering the market growth.

Antinuclear Antibody Test Market Opportunity

Automation and Digital Image Analysis to Offer Lucrative Growth Opportunity

In recent years, there has been an increasing shift toward automation and digital pathology. The automated immunofluorescence analyzers and AI-assisted image interpretation software are reducing dependency on expert readers, thereby enhancing throughput and reproducibility. As a result, key players are heavily investing in automated ANA workflows, creating long-term opportunities for market expansion.

• For instance, as of January 2026, the UNIQO 160, an advanced automation platform for indirect immunofluorescence assays (IFA), now features AI-driven result evaluation.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, by Key Countries/Region, 2025
• Technological Advancements in Antinuclear Antibody Test
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Segmentation

Analysis by Product

Based on the product, the market is segmented into reagents & assay kits, systems, and standalone consumables.

The reagents & assay kits segment is expected to hold a major share of the global market. The segment’s growth is attributed to continuous demand for reagents and assay kits compared to one-time instrument purchases. As a result, companies continue to expand their ANA assay portfolios, contributing to repeat purchases and higher market penetration of these products.

Analysis by Test Method

In terms of test method, the market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay, multiplex immunoassays, and others.

The immunofluorescence assay segment is expected to hold the major share of the global market during the forecast period. Over the past few years, the clinical guidelines have continued to recommend immunofluorescence assay as the preferred initial screening method due to its superior sensitivity and ability to detect diverse nuclear staining patterns. This is resulting in high adoption of this method, contributing to the segment’s growth.

Analysis by Indication

In terms of indication, the market is segmented into systemic lupus erythematosus (SLE), rheumatoid arthritis, sjögren’s syndrome, scleroderma, and others.

The rheumatoid arthritis segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is attributed to the chronic nature of rheumatoid arthritis and its growing prevalence worldwide. There is an increasing routine recommendation of ANA testing as part of autoimmune screening for patients with joint pain and related symptoms.

• For instance, according to data from the National Center for Biotechnology Information (NCBI), there were around 4,755,500 total cases of Rheumatoid arthritis in China in 2021.

Analysis by End-user

Based on end-user, the market is divided into hospitals, standalone laboratories, and others.

The hospitals segment is expected to hold the largest share of the global market during the forecast period. The growth is attributed to the higher volume of antinuclear antibody tests performed in hospital-based laboratories, due to frequent recommendations and faster results in these settings. Also, the partnerships between hospitals and manufacturers of ANA test kits are expanding product availability in these settings.

• For instance, according to the data from Laboratory of Florida LLC. in January 2026, there were 8,680 hospital-based labs in the U.S., which accounted for 55.0% of the total lab test volume in the country, including ANA tests.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for 42.3% share of the global antinuclear antibody test market in 2025. The region's growth is attributed to well-established diagnostic infrastructure, including standalone laboratories, physician laboratories, and clinical laboratories in the U.S., which supports higher utilization of antinuclear antibody test products.

• For instance, according to data from Laboratory of Florida LLC, as of January 2026, there were 5,414 independent labs, 106,190 physician office labs, 8,680 hospital labs, and 53,000 other labs in the U.S.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. Countries such as India, China, Japan, and South Korea are witnessing an increased demand for autoimmune screening due to improved access to rheumatology care, a shift in key players' manufacturing facilities, and an expanded distribution network. This is increasing the penetration of ANA testing products in the region, driving its growth.

Key Players Covered

The global antinuclear antibody test market is highly competitive, with several companies offering a range of reagents and kits at competitive costs and focusing on strengthening their product presence globally through expanding distribution networks and direct facility openings.

The report includes the profiles of the following key players:

• Bio-Rad Laboratories, Inc. (U.S.)
• Erba Mannheim (Germany)
• Trinity Biotech Plc. (Ireland)
• Thermo Fisher Scientific Inc. (U.S.)
• Antibodies Incorporated (U.S.)
• ZEUS Scientific, Inc. (U.S.)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• Immuno Concepts NA Ltd. (U.S.)
• ORGENTEC (Germany)
• Transasia Bio-Medicals (India)

Key Industry Developments

• June 2023: Revvity’s EUROIMMUN launched the UNIQO 160, a fully automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics, now available in countries that accept the CE mark to streamline the entire workflow from sample preparation through image acquisition and analysis.
• May 2022: ZEUS Scientific, Inc. received FDA clearance for ZEUS dIFine, an automated IFA imaging and pattern recognition system.